Dear Colleagues and Leaders in Oncology,

We write to you today as scientists, innovators, and founders committed to transforming how humanity understands, detects, and ultimately defeats cancer. We are Dr. Mones Abu-Asab and Mohamed Chaouchi, co-founders of Phyloncology, and we extend to you an open invitation—whether through collaboration, strategic partnership, or even acquisition—to explore a breakthrough approach that redefines cancer diagnostics.

---

Why Phyloncology Exists

After decades of research—spanning evolutionary biology, pathology, data science, and clinical studies—we reached a simple but profound conclusion: cancer cannot be solved by viewing it through the wrong analytical lens.

The oncology community has long been anchored to a mutation-centric view of cancer. From our work at the George Washington University School of Medicine and the NIH and through the engineering and computational frameworks we developed together, we have demonstrated that cancer is fundamentally an evolutionary imbalance rooted in cellular energy disruption.

This recognition led us to build Phyloncology, and with it, a phylogenetics-based diagnostic platform that treats cancer as what it truly is: an evolving system.

---

What We Bring to the Table

1. A Universal, Non-Biomarker-Dependent Diagnostic Method

Our technology does not rely on fragile, cancer-specific biomarkers. Instead, we use cladistics and phylogenetic analysis—the gold standard in evolutionary biology—to classify samples into healthy, transitional, or cancerous states.

This methodology is:

• Applicable across all cancer types
• Able to use any high-dimensional data (metabolomics, proteomics, gene expression)
• Resistant to cancer heterogeneity, which other analytical approaches treat as noise

2. Patented and Validated Technology

Our algorithm, conceived in 2005, patented in 2014, and refined through years of interdisciplinary development, preserves the full richness of biological data—without forcing statistical oversimplification.

3. Compelling Clinical Performance

Across multiple studies, our platform has shown exceptional promise:

• 100% separation of healthy vs. cancer patients in a prostate-cancer cohort using serum metabolomics
• Distinction between primary and metastatic tumors using gene-expression data
• Clear classification of male vs. female physiological signatures using serum data

These results validate a core principle: evolution tells the truth that statistics often hides.

4. Cost-Effective, Scalable, and Clinically Friendly

• Non-invasive: a simple blood draw
• Standard mass-spectrometry processing (~$100 per sample)
• Upload via web interface to generate real-time classification against a robust “master cladogram”

Once built, each cancer-type cladogram supports continuous, global deployment.

5. Clear, Realistic Deployment Paths

We have mapped out two viable strategies:

1. Regulatory Route:
   Approximately $1M needed for FDA approval of our first indication.
2. Market Adoption Route:
   Begin by building reference cohorts (500–1,000 samples per cancer type), integrate with labs, hospitals, and insurers, and scale diagnostics through a cloud-native platform.

---

Why the Oncology World Should Pay Attention

Despite remarkable technological advances, early cancer detection remains constrained by a biomarker-first mindset and analytical tools that aren’t built to handle evolutionary heterogeneity.

Phyloncology offers a new paradigm—one that uses heterogeneity as signal, not noise.

Our approach is not another dataset, biomarker, or statistical model. It is a fundamentally different analytical framework that reflects the biological reality of cancer.

---

An Open Invitation: Let’s Build the Future of Cancer Diagnostics Together

We believe Phyloncology has the potential to become a cornerstone technology for early detection. But to accelerate its impact, we welcome:

• Collaborations on pilot clinical studies
• Licensing or co-development partnerships
• Strategic acquisition discussions for organizations seeking a universal diagnostic engine
• Joint regulatory or commercialization pathways

You bring global reach, infrastructure, and clinical scale.
We bring a validated, patented, evolutionary platform with the potential to redefine detection.

Together, we can act faster—and save lives sooner.

---

Why Now

We are a small, focused team with a large vision. We have self-funded, avoided unnecessary dilution, and developed a platform built on decades of scientific rigor and engineering discipline.

But scaling a paradigm shift requires partners with the reach and resources to match the urgency of the mission.

Cancer won’t wait. Patients won’t wait. Neither should we.

---

A Call to Action

We invite you—the leaders shaping the future of oncology—to:

• Review our work and scientific foundations
• Engage with us in conversation
• Explore a pilot, partnership, or strategic alignment

If you are ready to embrace a truly evolutionary approach to cancer, we’re ready to collaborate.

Thank you for your time, your leadership, and your commitment to creating a future where early detection is accurate, universal, and accessible.

With deep respect and determination,

Mones Abu-Asab, PhD
Mohamed Chaouchi
Co-Founders, Phyloncology LLC

By Dr. Mones Abu‑Asab, PhD (co‑founder of Phyloncology LLC)

Drawing on 26 years at George Washington University School of Medicine and the National Institutes of Health, Dr. Abu‑Asab introduces a bold evolutionary lens to the study of cancer. His new book, Unraveling Cancer, reexamines the disease not as a collection of genetic errors, but as a deep-rooted evolutionary imbalance arising from the fundamental architecture of eukaryotic life.

📘 Key Themes & Innovations

• Evolutionary Origin: The book begins by tracing the evolutionary emergence of the eukaryotic cell, identifying clues to why multicellularity is inherently vulnerable to oncogenesis.
• Energy-Driven Hypothesis: It challenges conventional mutation-centric views, positing instead that disruptions in cellular energy dynamics are the primary spark for tumor initiation.
• Cancer Hallmarks & Microenvironment: It synthesizes classic hallmarks—like limitless replication and angiogenesis—with modern insights into metabolic shifts, microbial interactions, and the tumor milieu.
• Oncogenic Spectrum: Cancer is presented not as a uniform entity but as a spectrum influenced by energy flux, lineage history, and environmental context.
• Metastasis & Angiogenesis: These processes are reframed through ecological and evolutionary mechanisms, underlining their dynamic and adaptive nature.
• Microbiome Link: The interplay between host microbial ecosystems and tumor development is examined, aligning with recent studies in evolutionary oncology .
• Heterogeneity & Data Analysis: Emphasizing cancer’s intrinsic heterogeneity, Dr. Abu‑Asab argues that traditional average‑based analytics fall short. He advocates for phylogenetic and heterogeneity‑compatible bioinformatic tools—such as parsimony cladistics—to uncover meaningful tumor substructures .

🎯 Why It Matters

By integrating evolutionary theory, bioenergetics, tumor ecology, and sophisticated data analytics, Unraveling Cancer offers a cohesive and layered framework. Its aim is to deepen our understanding of cancer’s origins, drive diagnostic precision, and ultimately enrich therapeutic strategies.

Bottom line: This book redefines cancer as an evolutionary and energy‐centered phenomenon. It’s an essential read for researchers, clinicians, and data scientists seeking a fresh paradigm—one grounded in cellular evolution and ecological complexity.

Why haven’t you heard of the most promising early detection and diagnostic tool for cancer?

It’s a fair question—especially given its potential to save countless lives and transform cancer diagnosis on a global scale. Think of how Apple, Amazon, and Google reshaped the world. We believe this technology can have a similar level of impact—but in the realm of healthcare.

We discovered this tool in 2005, patented it in 2007 and received the actual patent in 2014, published peer-reviewed papers, and spoke to numerous researchers. And yet, we remain largely unknown. No big-name institution or lab. Just a small team of persistent, independent researchers with a universal solution—and unwavering belief in its power.

While much of the cancer research world focuses on identifying specific biomarkers for individual cancer types—often spending decades on a single subtype—we approached cancer from a radically different angle.

We asked: What if cancer, like all life forms, followed evolutionary patterns? What if we could apply phylogenetic analysis—a method universally accepted in biology to classify animals, plants, viruses, and bacteria—to cancer itself?

That’s exactly what we did.

And it worked. Across all cancer types.

Our tool doesn’t depend on narrow biomarkers or siloed cancer classifications. It uses a proven evolutionary framework to identify cancer universally—because we believe cancer itself is an evolutionary disease.

Yet, most cancer researchers we speak to are unfamiliar with the depth and power of phylogenetics. As a result, many conversations hit a wall—not because of disagreement, but because of a gap in expertise. And this knowledge gap has likely slowed the recognition of our work.

We’ve never pitched to angel investors. We’ve never stood on a stage. We’ve sent emails, LinkedIn messages, and filled out contact forms. But those likely ended up in junk folders, dismissed as spam, or overlooked as unsolicited outreach.

Why? Because we’re full-time professionals, sole breadwinners, and believed—perhaps naively—that if you build something truly excellent and publish it, people will notice.

But here’s what we know for sure:
This technology works. It is universal. It can change the trajectory of cancer diagnosis. And all it takes is one person to see its potential—to invest, to amplify, to help us bring it to the world.

So again, we ask:
Why haven’t you heard of the best early detection and diagnostic tool for cancer?

Because no one has given it ten minutes. Yet.